gefitinib — Medica
non-small cell lung cancer
Initial criteria
- age ≥ 18 years
- patient has advanced or metastatic disease
- patient has EGFR mutation-positive disease (e.g., exon 19 deletions, exon 21 (L858R) substitution mutations, L861Q, G719X, or S768I)
- the mutation was detected by an approved test
Approval duration
1 year